Literature DB >> 849392

Clinical and electrophysiological effects of intravenous quinidine in man.

D S Hirschfeld, C T Ueda, M Rowland, M M Scheinman.   

Abstract

Quinidine gluconate (total dose 4-4 to 9-1 mg/kg) was infused intravenously over 22 minutes in 20 patients with either frequent premature ventricular contractions or supraventricular arrhythmias, 16 of whom had bundle-branch block. Therapeutic plasma quinidine levels (3 to 7 mg/l) were achieved in 15. Heart rate, atrioventricular nodal, and infranodal conduction times did not change significantly. The QRS duration increased significantly from 128+/-30 to 134+/-29 ms at peak plasma quinidine levels (P less than 0.01). Mild hypotension occurred during infusion in most patients. Two patients had a severe but transient toxic response characterised by hypotension, nausea, vomiting, and diaphoresis. Atrioventricular dissociation with escape His bundle or fascicular rhythm occurred in 1 patient with sinus bradycardia. Bundle-branch block does not contraindicate administration of quinidine. Quinidine gluconate administered intravenously (0-3 to 0-4 mg/kg per min) is frequently associated with hypotenstion and should be used only in an intensive care setting and with careful monitoring of blood pressure.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 849392      PMCID: PMC483236          DOI: 10.1136/hrt.39.3.309

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  17 in total

1.  ELECTROPHYSIOLOGIC ANTAGONISM AND SYNERGISM OF POTASSIUM AND ANTIARRHYTHMIC AGENTS.

Authors:  Y WATANABE; L S DREIFUS; W LIKOFF
Journal:  Am J Cardiol       Date:  1963-11       Impact factor: 2.778

2.  Quinidine toxicity and its treatment. An Experimental study.

Authors:  R J LUCHI; J HELWIG; H L CONN
Journal:  Am Heart J       Date:  1963-03       Impact factor: 4.749

3.  A possible mechanism of action of quinidine.

Authors:  W C HOLLAND
Journal:  Am J Physiol       Date:  1957-09

4.  A study of substances which alter intraventricular conduction in the isolated dog heart.

Authors:  H H SWAIN; C L WEIDNER
Journal:  J Pharmacol Exp Ther       Date:  1957-06       Impact factor: 4.030

5.  Factors influencing conversion of chronic atrial fibrillation with special reference to serum quinidine concentration.

Authors:  R E BALL; M SOKOLOW
Journal:  Circulation       Date:  1956-10       Impact factor: 29.690

6.  The present status of therapy of the cardiac arrhythmias with quinidine.

Authors:  M SOKOLOW
Journal:  Am Heart J       Date:  1951-11       Impact factor: 4.749

7.  Utility and limitations of intravenous quinidine in arrhythmias.

Authors:  L J ACIERNO; R GUBNER
Journal:  Am Heart J       Date:  1951-05       Impact factor: 4.749

8.  Intravenous use of quinidine, with particular reference to ventricular tachycardia.

Authors:  A H CLAGETT
Journal:  Am J Med Sci       Date:  1950-10       Impact factor: 2.378

9.  Paroxysmal ventricular tachycardia; a study of 107 cases.

Authors:  C A ARMBRUST; S A LEVINE
Journal:  Circulation       Date:  1950-01       Impact factor: 29.690

10.  The mode of action of quinidine on isolated rabbit atria interpreted from intracellular potential records.

Authors:  E M VAUGHAN WILLIAMS
Journal:  Br J Pharmacol Chemother       Date:  1958-09
View more
  4 in total

Review 1.  Pharmacokinetics in patients with cardiac failure.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

3.  Drug-antibody-platelet interaction in quinine- and quinidine-induced thrombocytopenia.

Authors:  D J Christie; R H Aster
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

4.  Voltage- and time-dependent inhibitory effects on rat aortic and porcine coronary artery contraction induced by propafenone and quinidine.

Authors:  F Pérez-Vizcaíno; B Fernández del Pozo; F Zaragozá; J Tamargo
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.